Biogen MA Inc.

Biogen MA Inc. develops, manufactures, and commercializes human therapeutic products for neurological, autoimmune, and rare diseases. The company’s products include AVONEX, which is used for the treatment of relapsing multiple sclerosis (MS); PLEGRIDY, which is used for the treatment of relapsing forms of MS; TECFIDERA, an oral therapy used for the treatment of relapsing MS; FAMPYRA, a treatment to improve walking in adult patients with MS; and TYSABRI, a treatment for relapsing forms of MS in adults. It also provides ALPROLIX, a solution used for the control and prevention of bleeding episodes, perioperative (surgical) management, and routine prophylaxis in adults and children with hemophilia B; and ELOCTATE, a recombinant factor VIII therapy used for the control and prevention of bleeding episodes, perioperative (surgical) management, and routine prophylaxis in adults and children with hemophilia A. In addition, it offers GAZYVA, an injection used for the treatment of patients with previously untreated chronic lymphocytic leukaemia, and BENEPALI, an etanercept biosimilar used for the treatment of rheumatoid arthritis, axial spondyloarthritis, and plaque psoriasis. Further, the company provides RITUXAN, a solution for the treatment of relapsed, low-grade or follicular, CD20-positive, and B-cell non-Hodgkin’s lymphoma (NHL) as a single agent; for previously untreated diffuse B-cell, CD20-positive, NHL in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and other anthracycline-based chemotherapy regimens. Biogen MA Inc. was formerly known as Biogen Idec MA Inc. and changed its name to Biogen MA Inc. in March 2015. The company was founded in 1978 and is based in Cambridge, Massachusetts with manufacturing facilities in North Carolina, Denmark, Massachusetts, and internationally. As of November 12, 2003, Biogen MA Inc. operates as a subsidiary of Biogen Inc.